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A
tg4 is required for cleaving Atg8,
allowing it to be conjugated to
phosphatidylethanolamine on phago-
phore membranes, a key step in autopha-
gosome biogenesis. Deconjugation of
Atg8 from autophagosomal membranes
could be also a regulatory step in
controlling autophagy. Therefore, the
activity of Atg4 is important for autop-
hagy and could be a target for therapeutic
intervention. In this study, a sensitive and
specific method to measure the activity of
two Atg4 homologs in mammalian cells,
Atg4A and Atg4B, was developed using a
fluorescence resonance energy transfer
(FRET)-based approach. Thus LC3B
and GATE-16, two substrates that could
be differentially cleaved by Atg4A and
Atg4B, were fused with CFP and YFP at
the N- and C-terminus, respectively,
allowing FRET to occur. The FRET
signals decreased in proportion to the
Atg4-mediated cleavage, which separated
the two fluorescent proteins. This
method is highly efficient for measuring
the enzymatic activity and kinetics of
Atg4A and Atg4B under in vitro condi-
tions. Applications of the assay indicated
that the activity of Atg4B was dependent
on its catalytic cysteine and expression
level, but showed little changes under
several common autophagy conditions. In
addition, the assays displayed excellent
performance in high throughput format
and are suitable for screening and analysis
of potential modulators. In summary, the
FRET-based assay is simple and easy to
use, is sensitive and specific, and is
suitable for both routine measurement
of Atg4 activity and high-throughput
screening.
Introduction
Macroautophagy (hereafter referred to
as autophagy) is a major intracellular
degradation process conserved in all eukar-
yotic cells. Autophagy removes superfluous
components, damaged organelles, mis-
folded proteins and certain intracellular
pathogens via double-membraned auto-
phagosomes, which degrade their content
after fusing with lysosomes.
1,2 Autophagy
can also contribute to cellular dysfunction
and cell death under specific conditions.
3
The roles of autophagy in both cell
survival and cell death indicate that the
autophagy process can be an important
therapeutic target for diseases such as
neurodegeneration and cancer.
2,4,5
Autophagosome biogenesis requires two
ubiquitin-like conjugation systems: the
Atg12–Atg5 and the Atg8–phosphotidy-
lethanolamine (PE) systems.
6-8 The
cysteine protease Atg4 cleaves newly
synthesized Atg8 to reveal a glycine residue
required for covalent attachment to PE
(lipidation), and removes conjugated Atg8
from the autophagosome membranes
(delipidation) to facilitate autophagosome
biogenesis and Atg8 recycling.
9-11
While yeast express single genes encoding
Atg4 and Atg8, there are six human Atg8
homologs. The LC3 subfamily of Atg8
includes MAP1A/B light chain 3 (LC3A,
LC3B and LC3C), and the GABARAP
subfamily consists of c-aminobutyric acid
receptor-associated protein (GABARAP),
Golgi-associated ATPase enhancer of 16
kDa (GATE-16/GABARAPL2) and Atg8L
(GABARAPL1).
8,12,13 It seems that mole-
cules of the two subfamilies can differ in their
functions in autophagosome biogenesis.
14 In
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mammals there are four Atg4 homologs.
15
Atg4B is likely the principal human Atg4
homolog. It is able to cleave each of the
humanAtg8-relatedproteins testedsofarin
vitro and in living cells.
8,11,16,17 Studies have
also shown that Atg4A is a potent protease
for the GABARAP subfamily, but not the
LC3 subfamily, of Atg8 substrates, whereas
Atg4C and Atg4D seem topossess marginal
activities toward theAtg8homologs of both
subfamilies.
17,18
Blockage of Atg4-mediated Atg8 pro-
cessing could be an effective way to
interfere with autophagy. Toward that
end it would be critical to develop an
efficient, sensitive and specific method to
measure Atg4 activity. Several methods
have been used in previous studies.
Assessment of Atg4 activity has been
mainly based on an SDS-PAGE-based
assay,
9,17,19,20 which can be cumbersome
and highly variable with a relatively low
detection sensitivity. These methods
would be only suitable for in vitro analysis
and cannot be formatted for high-through-
put analysis. Several fluorescence or lumin-
escence-based assays, which utilize
substrates that emit signals after cleavage
by Atg4, have been developed for in vivo
use or for high throughput screening.
21,22
While versatile and sensitive, these meth-
ods are prone to nonspecific interference
due to their design.
Here, we report the development of a
novel Atg4 assay based on fluorescence
resonance energy transfer (FRET). We
used cyan fluorescence protein (CFP) as
the donor and yellow fluorescence protein
(YFP) as the receptor, which were fused to
the N-and C-termini of the Atg8 sub-
strates, respectively. Cleavage of the fusion
protein by Atg4A or Atg4B led to a
proportional loss of FRET signals. We
found this assay sensitive, specific and
reproducible for routine analysis of the
Atg4 activity and kinetics, and for high
throughput screening.
Results
FRET-Atg8 fusion substrates can be
cleaved by Atg4. When a suitable pair of
fluorophores is brought within close proxi-
mity (10–100 Å) of one another, excitation
of the donor molecule can result in energy
transfer to the acceptor fluorophore.
23 CFP
and YFP are one of the most common pairs
used for FRET constructs. The structures
of LC3B and GATE-16 suggest that the N
terminus and the C terminus of these
proteins are spatially close to each
other.
24,25 We hypothesized that C- and
N-terminal fusions of YFP and CFP to the
full-length LC3B or GATE-16 would
allow FRET to occur, and that cleavage
of the products would lead to the separa-
tion of the two fluorescent moieties, thus
causing the loss of the FRET signals
(Fig.1A). We verified that these fusion
proteins, collectively termed FRET-Atg8,
could be efficiently processed by Atg4A
and Atg4B using the well-established SDS-
PAGE method (Fig.1B and C). FRET-
LC3B was rapidly cleaved by Atg4B,
generating the CFP-LC3B and the YFP
fragments. This reaction was specific since
the substrate could not be processed by
Atg4A or the Atg4B catalytic mutant,
Atg4B
C74S. Consistently, the cleavage site
mutant, FRET-LC3B
G120A, was not
digested by Atg4B (Fig.1B). In contrast,
both Atg4A and Atg4B, but not Atg4B
C74S,
effectively cleaved FRET-GATE-16
(Fig.1C). Under the experimental condi-
tions tested, nearly all FRET-GATE-16
and up to 80% of FRET-LC3B could be
processed within 20 min (Fig.1B and C),
and nearly all FRET-LC3B could be
processed within 60 min (data not shown).
These results were consistent with previous
studies,
17 indicating that the fusion mole-
cules remained effective substrates for
Atg4A and/or Atg4B.
Cleavage of FRET-Atg8 substrates by
Atg4 can be specifically measured with
changes in the FRET signal. We then
determined whether the fusion molecules
could generate FRET signals that were
sensitive to cleavage (Fig.2A). FRET-
GATE-16 and FRET-LC3B were exam-
ined by fluorescence spectrometry in the
absence or presence of Atg4B. Both the
donor (CFP) and the acceptor (YFP)
emission wavelengths can be measured
when excited at the wavelength of 434
nm. Thus, the full spectrum scan indicated
that both fusion proteins had a major
emission peak at 527 nm, and a minor
emission peak at 477 nm in the absence of
Atg4A or Atg4B as expected, indicating
that the FRET signals were maintained
(Fig.2B). However, when an Atg4
enzyme was present, the 527 nm/477 nm
ratio decreased from 1.65 to 0.69 for
FRET-LC3B, and from 1.8 to 0.6 for
FRET-GATE-16 (Fig.2B).
The relative fluorescence unit (RFU)
ratio of 527 nm to 477 nm could thus be a
sensitive measurement of the Atg4 cleav-
age activity. To examine this hypothesis,
we compared the FRET signal (ratio of
527 nm/477 nm) during the cleavage of
the fusion proteins by Atg4A, Atg4B or
Atg4B
C74S (Fig.2C). Atg4B significantly
reduced the FRET signal of FRET-LC3B
and FRET-GATE-16 in 10 min, whereas
Atg4B
C74S did not. On the other hand,
Atg4A significantly reduced the FRET
signal of FRET-GATE-16 but not that of
FRET-LC3B, consistent with the fact that
FRET-LC3B cannot be cleaved by Atg4A.
The reduction of FRET signal was not due
to nonspecific degradation of the FRET
substrates, as no FRET reduction was
observed in the absence of Atg4 enzymes
or if the substrate contained the cleavage
site mutant (LC3B
G120A)( Fig.2C). Thus,
these results indicated that the FRET-
based assay was specific and sensitive to
Atg4-mediated cleavage.
Measurement of the kinetics of Atg4A
and Atg4B using the FRET-based assay.
We had previously determined the kinetic
parameters of all four Atg4 homologs
toward LC3B and GATE-16 using the
SDS-PAGE-based method.
17 To deter-
mine whether the FRET-based assay
could also be used to measure the kinetics
of cleavage, we incubated Atg4A or Atg4B
with FRET-GATE-16 or FRET-LC3B,
respectively, at different concentrations.
The ratio of the fluorescence intensity
(RFU) at 527 nm and 477 nm was in
proportion to the substrate concentrations
and the corresponding cleavage products,
suggesting that the assay was suitable for
kinetics analysis (Fig.3A). The initial
velocity of the cleavage was thus deter-
mined based on the change of the 527
nm/477 nm ratio and then plotted against
the substrate concentrations. From the
fitted curve, the key kinetic parameters,
Vmax and KM, were derived (Fig.3B–D).
The data indicated that Atg4B had a
higher affinity and a higher catalytic
efficiency than Atg4A toward the two
substrates. GATE-16 was a better sub-
strate than LC3B, particularly for Atg4A,
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which could not cleave LC3B. These
findings were consistent with previous
determinations using LC3B-GST and
GATE-16-GST as the substrates in an
SDS-PAGE-based assay.
17,22 The catalytic
efficiency of Atg4B toward FRET-GATE-
16 (221,000 mol
21S
21, Fig.3D) was in the
same order of magnitude as that toward
GATE-16-GST (107, 000 mol
21S
21)
17
despite the different assay formats used
for the measurement. The catalytic effi-
ciency of Atg4B toward LC3B-GST
17 and
FRET-LC3B (Fig.3D) was also quite com-
parable (89,600 vs 120,000 mol
21S
21).
These observations are consistent with
the notion that Atg4B is less selective
toward the substrates and their config-
urations. On the other hand, it is noted
that Atg4A is more selective than Atg4B
in substrate preference, only being able
to hydrolyze the GABARAP subfamily
substrates, and is therefore likely more
sensitive to the configuration of the
substrate. Consistently, the catalytic effi-
ciency of Atg4A toward FRET-GATE-16
(1,310 mol
21S
21, Fig.3D) seemed to be
particularly lower than that toward
GATE-16-GST (12,800 mol
21S
21),
17
showing a preference toward GATE-16-
GST over FRET-GATE-16.
Measurement of Atg4 activities in cell
lysates using the FRET-based assay.
While the above studies used purified
recombinant Atg4 proteins, we sought to
determine whether the FRET assay would
be also effective for the measurement of
Atg4 activity in biological samples. We
investigated this issue by examining the
activity of Atg4B in the following studies.
Lysates prepared from HEK-293A cells
with or without various overexpressed
Atg4 constructs were incubated with the
FRET-LC3B substrate. While the SDS-
PAGE-based assay clearly revealed the
difference in the extent of FRET-LC3B
cleavage with the overexpressed Atg4B
(Fig.4A), the FRET-assay provided a
more quantitative measurement (Fig.4B).
Thus, while only about 10% of incubated
FRET-LC3B (3 mg) was cleaved by the
endogenous Atg4B in 20 mg of lysates in
5 min, nearly 100% of the same amount of
FRET-LC3B could be cleaved by 20 mgo f
lysates from Atg4B-overexpressing cells,
and nearly 90% of cleavage was reached
with 5 mg of such lysates. The over-
expression of neither Atg4B
C74S (Fig.4B)
nor Atg4A (Fig.4A) caused an elevation of
the cleavage above the level reached by the
endogenous Atg4B. Conversely, knock-
down of Atg4B by about 50% led to the
reduction of the cleavage by 60% in a
30 min reaction (Fig.4B). Thus, theFRET
assay could specifically and quantitatively
measure the Atg4B activity in a biological
sample.
To determine whether the assay could
discriminate Atg4B activity in cells consti-
tutivelyexpressing different levels of Atg4B,
we analyzed a panel of 4 breast cancer lines
and found that the Atg4B activity was well
correlated with the expression level of
Atg4B, with MDA-MB-231 being the
lowest, followed by MCF7, MDA-MB-
436 and MDA-MB-468 (Fig.4C). The
Figure1. Verification of the cleavage of FRET substrates by Atg4 using SDS-PAGE. (A) Schematic representation of the FRET-LC3B and FRET-GATE-16
constructs. The cleavage site of LC3B and GATE-16 at the glycine (G) residue is indicated. (B and C) FRET-LC3B, FRET-LC3B
G120A (B) or FRET-GATE-16
(C) (5 mg) were incubated with Atg4B, Atg4B
C74S or Atg4A (0.25 mg), respectively. The reaction was stopped at different times using SDS-PAGE sample
buffer. The substrates and the cleaved products were separated by SDS-PAGE and examined by CBB staining. Representative gel images from three
independent experiments are shown in the left panels. Percentage of cleaved substrate was calculated based on the densitometry of protein bands
of the representative experiments (right panels).
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cleavage activity was fully suppressed by N-
ethylmaleimide (NEM), a general cysteine
protease inhibitor.
Considering these data, we next sought
to determine whether the Atg4B expression
and activity could change during autophagy.
Incubation of cells in EBSS, a starvation
medium, did not alter the expression of
Atg4B in the breast cancer cell lines
(Fig.4C, a) and in HEK-293A cells
(Fig.4D, a). Consistently, application of
other chemicals that affect autophagy,
such as rapamycin, N-acetylcysteine, or
bafilomycin A1, did not change the
Atg4B expression level (Fig.4D, a), or
Figure2. Verification of the cleavage of FRET substrate by Atg4 using the FRET-based assay. (A) Schematic representation of the assay principle. The FRET
signal (lem = 527 nm) is reduced as the result of cleavage, which separates the CFP (donor) moiety from the YFP (acceptor) moiety. (B) The fluorescence
emission spectra of FRET-GATE-16 or FRET-LC3B before and after cleavage. Substrate (500 mg/ml) were mixed with buffer, Atg4A (100 mg/ml) or Atg4B
(2 mg/ml) in a cuvette in the volume of 0.5 ml for 30 min. Data from representative experiments were collected on a Cary Eclipse spectrophotometer. The
excitation wavelength was 434 nm. Emission peaked at 477 nm with Atg4 present, but at 527 nm with no Atg4 present in the reactions. In the presence
of the corresponding Atg4 enzyme, the ratio of 527 nm/477 nm for FRET-GATE-16 decreased from 1.8 to 0.6 and that for FRET-LC3B was reduced from
1.65 to 0.69. (C) FRET-LC3B, FRET-GATE-16 and FRET-LC3B
G120A (100 mg/ml) were incubated with Atg4A, Atg4B, or Atg4B
C74S (2 mg/ml) in a volume of 200 ml
for 10 min. The fluorescence ratios of 527 nm/477 nm at the beginning and at the 10 min point were determined. Data represent the mean ± SD from
three independent experiments. ***p , 0.001 (paired t-test, panel C).
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the activity (Fig.4D, b). These data indi-
cate that the cleavage potency of Atg4B
was more dependent on the expression
level than on the autophagy status. This
notion, however, does not rule out the
possibility that Atg4 activity could vary
inside the cells following proper auto-
phagy stimulation,
26 but failed to be
detected in the in vitro condition.
Configuration of the FRET-based
assay for high-throughput screening
(HTS). One major advantage of the
FRET assay over the SDS-PAGE-based
assay is that it can be easily configured to
a high-throughput format for analysis or
for screening. To ascertain HTS compat-
ibility and robustness, we examined the
performance of the FRET assay in mul-
tiple replicates in 384-well plates.
An important parameter for evaluating
the reliability and robustness of the high-
throughput assay is the Z’ factor.
27 This
factor evaluates the size of the errors in the
data relative to the difference in the
maximum and minimum values in
the assay, which gives rise to an estimate
of the assay window. The Z’ factor can
assume any value # 1. A Z’ factor of 1
denotes an ideal assay with complete
separation of positive and negative con-
trols. Z’ factor . 0 denotes separation
between the means ± 3 SD of the positive
and negative control. In HTS, Z’ factors
of . 0.5 are considered excellent. We
determined that the Z’ factors for the
Atg4A FRET-GATE-16 assay and the
Atg4B FRET-LC3B assay were 0.78 and
0.81, respectively (Fig.5), which indicated
a robust performance of these assays. Thus,
the FRET-based Atg4 assay has the quality
to be successfully employed in HTS.
Analysis of chemical interference of
Atg4 activity using the FRET-based
assay. The FRET assay would allow for
a better quantitative determination and
comparison of various enhancing or inhib-
iting modulators of Atg4 enzymes. Using
this assay, we first examined the effect
of six representative protease inhibitors
on Atg4A and Atg4B activities. These
chemicals include a disulfide bond reducer,
tris-2-carboxyethyl-phosphine (TCEP), a
sulfhydryl group blocker, N-ethylmaleimide
(NEM), a serine protease inhibitor, 4-
(2-aminoethyl) benzenesulfonyl fluoride
hydrochloride (AEBSF), a general cysteine
protease inhibitor, E64-D, a general
Figure3. Determination of the kinetics of Atg4A and Atg4B using the FRET-based assay. (A–C) FRET-LC3B and FRET-GATE-16 at different concentrations
(25 mg/ml to 500 mg/ml) were incubated with Atg4B (2 mg/ml in A, 0.5 mg/ml in B) or Atg4A (2.5 mg/ml, C) for 30 min at 37°C. The RFUs at 527 nm and
477 nm were determined and the ratios were calculated (A). The initial velocity (V, y-axis) at each substrate concentration was defined as the increment
of the substrate per second ([mM]/s), and was calculated based on RFU at the 5 min time point of the reaction for Atg4B (B) or at the 30 min time point of
the reaction for Atg4A (C) The velocity was then plotted against the concentration of the substrate (S [mM], x-axis). The curves were fitted using the
ligand-binding method (SigmaPlot 10.0). (D). The kinetic parameters KM and kcat/KM were derived from the fitted curves. Data represent the mean ± SD
from three independent experiments. ***p , 0.001 (paired t-test, A).
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Figure4. For figure legend, see page 407.
406 Autophagy Volume 8 Issue 3© 2012 Landes Bioscience.
Do not distribute.
Figure4 (See opposite page). Measurements of Atg4B activity in cell lysates using the FRET-based assay. (A) HEK-293A cells were transfected with Flag-
Atg4A, Flag-Atg4B or vector for 24 h. Cells were harvested and cell lysates (25 mg) were mixed with FRET-LC3B (5 mg) for 20 min before the reaction was
stopped by the addition of sample loading buffer, and separated by SDS-PAGE. The expression level of Flag-Atg4A and Flag-Atg4B was detected by
immunoblot assay using an anti-Flag antibody. The cleavage was assessed after CBB staining. (B) HEK-293A cells were transfected with Flag-Atg4B, Flag-
Atg4B
C74S or the control vectors. Alternatively, they were transfected with a control siRNA or a siRNA against Atg4B. Cell lysates (20 mg) were prepared
and subjected to immunoblot analysis (a), or incubated with FRET-LC3B (3 mg) for the cleavage assay (b). Five micrograms (indicated) or 20 mg (all others)
of lysates were used. WT, control; KD, control or Atg4B siRNA-treated. The percentage of substrate cleavage (c) was calculated. (C) Four breast cancer cell
lines were cultured in complete medium (CM) or EBSS for 4 h. Cell lysates (20 mg) were prepared and subjected to immunoblot analysis (a), or incubated
with FRET-LC3B for the cleavage assay (b). A positive control group with purified recombinant Atg4B (2 mg) was included. A generic cysteine protease
inhibitor, NEM (100 mM), was included in some reactions as indicated. The percentage of substrate cleavage (c) was calculated. (D) HEK-293A cells were
incubated in EBSS, or in complete medium alone (CM) or with rapamycin (Rap, 2 mM), N-acetylcysteine (NAC, 20 mM) or bafilomycin A1 (Baf, 1 mM) for 4 h.
Cell lysates were prepared and subjected to immunoblot analysis (a), or incubated with FRET-LC3B for the cleavage assay (b). A positive control group
with purified recombinant Atg4B (2 mg) was included (indicated as Atg4B). Data represent the mean ± SD from three independent experiments.
***p , 0.001 (one way ANOVA, B, c; and C, c).
Figure5. Determination of the performance of the FRET-based Atg4 assay in a high-throughput format. Atg4A (10 mg/ml, A) or Atg4B (2 mg/ml, B) were
mixed with 60 mg/ml of FRET-GATE-16 (A) or FRET-LC3B (B) in a total volume of 20 ml in 384-well plates. After 60 min incubation, the RFU ratio of 527 nm/
477 nm was determined for each of the reactions in 192 wells (solid circle). Control reactions with no Atg4 enzymes were set up in the same way (open
circle). The ranges of the maximal and minimal values ± three standard deviations were indicated and the Z’ factors for both Atg4A and Atg4B assays
were calculated.
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aspartic peptidase inhibitor, pepstatin A,
and an aminopeptidase inhibitor, bestatin.
We found that only NEM, but not
other chemicals at the tested concentrations,
was able to inhibit the activity of Atg4A
and Atg4B (Fig.6A and B), consistent
with previous findings.
15,18 This indicates
that while the cysteine residue of Atg4A
and Atg4B is important for enzymatic
activity, generic cysteine protease inhibi-
tors, such as E64-D, are not effective
in suppressing this activity. Consistently,
Figure6. Assessment of selected protease inhibitors on Atg4 using the FRET-based assay. (A and B) Atg4A (10 mg/ml, A) or Atg4B (2 mg/ml, B) were
incubated with the indicated compounds (10 mM) for 30 min at 37°C in a 384-well plate. The FRET signal was recorded after adding FRET-GATE-16 (A) or
FRET-LC3B (B) (50 mg/ml) to a total volume of 50 ml. The RFU ratios of 527 nm/477 nm at the reaction time of 60 min (A) or 30 min (B) were determined.
The relative Atg4 cleavage activity was expressed using the ratios normalized to that of the control (buffer only). (C and D) Atg4A (10 mg/ml, C) or Atg4B
(2 mg/ml, D) were incubated with NEM at different concentrations (0–1,000 mM) for 30 min at 37°C in a 384-well plate. FRET-LC3B (50 mg/ml) was then
added and the fluorescence signals at 477 nm and 527 nm were measured consecutively in the next 60 min (C) or 30 min (D) and the ratios of 527 nm/
477 nm were determined. (E and F) The percentages of inhibition on the activity of Atg4A (E) or Atg4B (F) in the presence of different concentrations of
NEM at the time when maximal cleavage was achieved (60 min for Atg4A, E, 30 min for Atg4B, F) were calculated. The IC50 was then determined for each
enzyme-compound combination. Data represent the mean ± SD from three independent experiments. ***p , 0.001 (one way ANOVA, A and B).
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TCEP showed an enhancing effect on the
reaction, especially for Atg4A, suggesting
the importance of maintaining cysteine
residues in reduced status.
To determine the potency of NEM,
different concentrations of NEM were
applied and the RFU ratio of 527 nm/
477 nm of the cleavage reaction was
reversed in a concentration-dependent
manner (Fig.6C and D). The IC50 was
determined to be 10 mM for Atg4A and
17.7 mM for Atg4B (Fig.6E and F). Thus,
the FRET-based Atg4 assay can quantita-
tively determine the effects of small
molecule modulators of Atg4A and Atg4B.
Discussion
The mammalian Atg8 homologs are a
group of proteins with diverse sequences,
belonging to two subfamilies, the LC3
subfamily and the GABARAP subfamily.
Diversity in their function has been
reported in which LC3B seems to be
mostly involved in the elongation of the
phagophore membrane, whereas GATE-
16 is more important for autophagosome
maturation at a later stage.
14 The initial
processing of Atg8 molecules requires the
cysteine protease Atg4, which has multiple
mammalian homologs. While Atg4A and
Atg4B have potent enzymatic activities,
Atg4C and Atg4D seem to have only
minor effects on Atg8 processing, and
their physiological significance is not
clear.
17,18,28,29 Atg4B has the widest sub-
strate spectrum, being able to cleave
mammalian Atg8 homologs of both sub-
families. Deletion of Atg4B led to signific-
ant defects in the lipidation of all Atg8
molecules.
30 Interestingly, the phenotypes
of Atg4B-deficient mice are limited to
inner ear development and balance func-
tions,
30 suggesting that its function could
be complemented by other Atg4 homo-
logs, such as Atg4A. The latter is able to
process the GABARAP subfamily of Atg8
proteins, but not the LC3 subfamily of
Atg8 proteins. Thus the functional com-
plementarity of Atg4 homologs could be
based on the functional complementarity
of the two Atg8 subfamilies. It also seems
importantthatboth Atg4A andAtg4Bneed
to be affected if endogenous regulatory or
exogenous intervening mechanisms are to
be exerted at this level of autophagy
function. Methods that allow rapid detec-
tion of Atg4A and Atg4B activities with a
great sensitivity and specificity are needed
to understand these mechanisms.
Several approaches to measuring Atg4
activity have been developed. The classical
method is based on electrophoretic sep-
aration of cleaved substrates on SDS-
PAGE, using Atg8 substrates fused with
a tag C-terminal to the cleavage site.
9,19,20
The fused tag allows the detection of
cleavage based on either the change of the
size of the substrate or the appearance of
the C-terminal cleavage products. This
method has been used widely with no
need for special equipment. We have
successfully used this method to determine
the kinetic parameters of all mammalian
Atg4 homologs.
17 The SDS-PAGE-based
method is, however, rather cumbersome
for quantification of the cleavage, is less
suitable for regular cellular samples than
recombinant Atg4, and is certainly not
adaptable for high throughput.
Subsequent assay development had
been focused on the aspects of being more
quantitative and sensitive, while adopting
the principle of using fusion substrates. A
successful example is the use of phospho-
lipase A2 (PLA2) as the fusion partner of
LC3B.
21 After cleavage by Atg4B, PLA2 is
separated from LC3B and regains its
enzymatic activity, which is detected with
a secondary fluorogenic assay. Thus the
activity of PLA2 is in proportion to the
level of LC3B-PLA2 cleavage, or Atg4B
activity. This method seems to be very
sensitive and specific, and is suitable for
high throughput screening. However, one
possible concern for the two-reaction
design is that interference with the PLA2
reaction may be mistakenly attributed to
the change in the Atg4 activities.
22,31
To detect Atg4 activity in situ, two
other methods have been developed. One
uses a LC3B fusion construct that con-
tains Gaussia luciferase and β-actin, which
would allow the hybrid molecule to be
sequestered inside the cells in the actin
network.
21 The cleavage by Atg4B results
in the release of Gaussia luciferase, which
is exported to the extracellular space where
it can be measured by luminometry. This
assay is also a coupled assay in which the
luciferase reaction may render the assay
prone to changes not related to the Atg4
activity. In addition, the introduction of
the luciferase fusion construct to the cell
can be labor intensive. Recently, a simpli-
fied one-reaction design has been pro-
posed.
26 This system uses FITC-labeled
Atg4 substrate peptides conjugated to
polymeric nanoparticles, which are highly
permeable to cells. Once inside the cells,
the peptides are cleaved by Atg4, releasing
and dequenching the labeled fluorescent
dye. The fluorescence is captured by a
CCD camera and the intensity reflects
the Atg4 activity. The advantage of this
system is that there is no involvement of
any secondary reactions and there are no
complicated methods needed to introduce
the substrate into cells. A different concern
is the use of a 4-amino acid peptide based
on the consensus sequence of several Atg8
homologs, instead of the full length
proteins, as the substrate of Atg4 will
likely reduce the efficiency of the cleavage
reaction because of the requirement for
conformational change of the enzyme
triggered only by the full-length sub-
strates.
17,20,22 In general, these “in vivo”
assays may be suited for analysis of Atg4
activity in situ, but the substrate may be
rapidly hydrolyzed by the high basal level
of Atg4 activity as soon as it is introduced
into cells. These assays are also in general
difficult to be configured to the high
throughput format.
The assay reported in this study uses
FRET-based substrates and is able to
sensitively detect cleavage by changes in
fluorescence intensity at two different
wavelengths. Much less substrate is needed
in this assay compared with theSDS-PAGE
based assay. In addition, the FRET-based
assay delivers time- and dose-dependent
quantitative responses and has a broad
dynamic range sufficient for quantifying
and discriminating Atg4 activities under
different conditions. The use of a full-
length molecule as the substrate can ensure
maximal specificity and hydrolysis effi-
ciency and at the same times allow both
the LC3 and the GABARAP subfamily
substrates to be used to differentiate the
activity of Atg4A and Atg4B. It would be
also less prone to interference than other
fluorescence/luminescence based assays as
the signals are directly coupled with the
Atg4 activity without the involvement of a
secondary reaction.
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With these properties, this assay has
been successfully used to determine the
kinetic properties of the recombinant
Atg4A and Atg4B enzymes, to determine
Atg4 activity in cell lysates, and to assess
the potency of chemical inhibitors. The
robust performance of the assay in high
throughput format suggests that it is
suitable for screening chemical modula-
tors. Finally, although not examined in
this study, the FRET-substrate construct
can be transfected into cells to analyze
Atg4 activity in situ. It is thus believed that
this FRET-based Atg4 assay has overcome
some of the key limitations of current
methodology and offers an efficient way to
determine Atg4 activity under a variety of
conditions.
Materials and Methods
Chemicals, antibodies, bacterial stains
and plasmids. All chemical reagents were
obtained from Sigma-Aldrich unless other-
wise stated. Anti-Flag was obtained from
Sigma-Aldrich (F3165), anti-Atg4B was
from Abgent (Ap1809c), anti-GAPDH
was from Novus (NB300-221) and sec-
ondary antibodies conjugated with HRP
were from Jackson Immunochemicals
(115-035-062 and 111-035-045). The
Escherichia coli strain BL21 (DE3) and
the plasmid pcDNA3.1 (+) (V790-20)
were from Invitrogen. The plasmid pET-
28a (+)(69864) was from Novagen, and
pEYFP-C1 (6004-1) and pECFP-C1
(6075-1) were from Clontech.
Protein expression and purification.
The open reading frames encoding human
Atg4A, Atg4B, Atg4B
C74S, LC3B and
GATE-16 were cloned and constructed
as previously described.
17 To express
LC3B and GATE-16 with the N-terminal
His-CFP-tag and C-terminal YFP-tag in
E. coli, full-length LC3B or GATE-16 was
first cloned into pET-28a (+) between the
BamHI and HindIII restriction sites. The
DNA fragment of ECFP and YFP were
amplified from the commercial vectors
pECFP-C1 and pEYFP-C1. ECFP was
inserted at the N-terminal side of LC3B
or GATE-16 at the NdeI and BamHI
sites, whereas YFP was inserted at the
C-terminal side at the HindIII and XhoI
sites. This resulted in six additional nucleo-
tides at both fusion sites. FRET-LC3B
G120A
was constructed using the ExSite in vitro
site-directed mutagenesis system (Agilent
Stratagene). All constructs were confirmed
by sequencing and transformed into BL21
(DE3) for expression following IPTG
(Research Products International Corp.,
I56000) induction. Expressed proteins
were purified by affinity chromatography
using PrepEase (USB, 78796) and gel
filtration using a Superdex 75 column
(GE Health, 17-1068-01), and verified
by SDS-PAGE and Commassie Brilliant
Blue (CBB) staining.
Cell culture, transfection and immuno-
blot assay. HEK-293A cells were grown
in DMEM containing 10% fetal bovine
serum and 1% antibiotics. To express
Atg4 tagged with Flag in mammalian cells,
the cDNA fragments encoding Atg4A,
Atg4B and Atg4B
C74S with the tag were
introduced into the mammalian expres-
sion vector pcDNA3.1 (+). HEK-293A
cells were transfected with the indicated
constructs using Lipofectamine 2000
transfection reagent (Invitrogen, 11668-
027) according to the manufacturer’s
instruction. After 24 h incubation, trans-
fected cells were harvested and lysed with
Buffer A (150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1 mM glycerophosphate,
1m MN a 3VO4, 1% Triton X-100,
50 mM TRIS-HCl, pH 7.5). To suppress
the endogenous expression level of Atg4B,
siRNA against Atg4B (SantaCruz Biotech,
sc-72584) was transfected into HEK293A
cells using Oligofectamine (Invitrogen).
For immunoblot assay, lysates were
separated by SDS-PAGE and transferred
to PVDF membranes. After the application
of the appropriate antibodies, signals were
developed using Immobilon Western detec-
tion kit (Millipore, WBKLS0500) accord-
ing to the manufacturer’s instructions.
Analysis of the Atg4-mediated cleavage
of FRET-substrates by SDS-PAGE.
Purified FRET-LC3B, FRET-LC3B
G120A
and FRET-GATE-16 (5 mg) were mixed
with 0.25 mg of purified Atg4A, Atg4B
or Atg4B
C74S or 25 mg of HEK-293A cell
lysate in Buffer B (150 mM NaCl, 1 mM
EDTA, 50 mM TRIS-HCl, pH 7.5). After
incubation at 37°C for different times the
reactions were stopped by the addition of
sample buffer, separated by SDS-PAGE
and examined by CBB staining. The
full-length protein (CFP-LC3B-YFP and
CFP-GATE-16-YFP) would be cleaved
into CFP-LC3B or CFP-GATE-16, and
YFP by the proper Atg4. The percentage
of cleavage was calculated as previously
described.
17 Briefly, the optical density
(OD) of the product protein bands is
divided by the OD of all the protein bands:
percentage of cleavage (%) = 100% *
(ODYFP +O D CFP-LC3B/CFP-GATE-16)/
(ODYFP +O D CFP-LC3B/CFP-GATE-16 +
ODFRET-LC3B/FRET-GATE-16).
Measurement of Atg4 activity using
the FRET-based assay. Purified Atg4A
and Atg4B proteins or cell lysate were
mixed with FRET-LC3B or FRET-
GATE-16 in Buffer B. The assay volumes
were 400 ml (cuvette format), 200 ml (96-
well format) or 20–50 ml (384-well format,
respectively. After incubation at 37°C for a
given time, the cleavage of the substrates
was measured using a fluorescence spec-
trometer (Cary Eclips, Agilent, or M5,
Molecular Device). The excitation wave-
length was 434 nm. Emission was meas-
ured at 477 nm (CFP) and 527 nm (YFP
or FRET). The RFU ratio of 527 nm/477
nm was calculated and used to determine
the degree of cleavage since it decreased
proportionally to the extent of substrate
cleavage. The percentage of cleavage of the
substrates was thus determined based on
the proportion of the total RFU change,
which is calculated as following: percent-
age of cleavage (%) at a given condition (x)
= (RFUmax - RFUX)/(RFUmax - RFUmin))
*100%, in which the RFUs are the
527 nm/477 nm ratios of reactions under
no cleavage (RFUmax), under highest
cleavage (RFUmin), and under a given
condition (RFUX).
Measurement of Atg4 kinetics using
the FRET-based assay. Both FRET-
LC3B and FRET-GATE-16 can be effi-
ciently cleaved by Atg4B at a dose of
25–500 mg/ml. Atg4A or Atg4B were
incubated with FRET-LC3B or FRET-
GATE-16 at different concentrations in
Buffer B in a total volume of 200 mla t
37°C for the designated times. The
kinetics were determined as previously
described
32 with modifications. In brief,
the initial velocity of the cleavage reaction
was defined as V = [S]t/t, in which [S]t
is the substrate concentration ([S]) at a
given time point (t). [S]t was estimated
based on the fluorescence change of the
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substrates at 527 nm ([S]t-527nm) as well as
on the fluorescence change of the sub-
strates at 477 nm ([S]t-477nm), so that [S]t
= ([S]t-527nm + [S]t-477nm)/2. [S]t-527nm
was calculated as [S]*(RFUmax-527nm −
RFUt-527nm)/(RFUmax-527nm − RFUmin-
527nm), whereas [S]t-477nm =[ S ] * ( R F U t-477nm
− RFUmin-477nm)/(RFUmax-477nm −
RFUmin-477nm), in which [S] is the initial
substrate concentration, RFUmax and
RFUmin are the fluorescence intensity at
the maximal and minimal levels across
the entire reaction period at the corres-
ponding wavelength, and RFUt is the
fluorescence intensity at a given time (t).
The initial velocity (V) was then plotted
against the concentration of the sub-
strate at the given time points ([S]t) and
the curve was fitted using the ligand-
binding method (SigmaPlot 10.0, Systat
Software), from which the Vmax ([S]/sec)
and KM (Michaelis constant, [S]) for each
enzyme-substrate reaction were derived
based on the Michaelis-Menten formula.
The catalytic constant (kcat, sec
21)w a s
determined by dividing Vmax by the
concentration of the enzyme. The cata-
lytic efficiency is defined as kcat/KM
(mol
21Lsec
21).
High-throughput screening format of
the Atg4 assay. Atg4A (10 mg/ml) or
Atg4B (2 mg/ml) were first incubated with
chemical compounds (10 mM) for 30 min
at 37°C in 384-well plates. FRET-GATE-
16 or FRET-LC3B (60–100 mg/ml) was
then added to a total volume of 20–
50 ml. After 30 min (for the Atg4B/
FRET-LC3B reaction) or 60 min (for
the Atg4A/FRET-GATE-16 reaction), the
fluorescence intensity was recorded.
The relative cleavage activity of Atg4A
or Atg4B was calculated based on the
change of 527 nm/477 nm ratio as
described above. The positive control for
the cleavage was without any chemicals,
whereas the negative control was without
the Atg4 enzyme. The performance of
the screening was measured by the Z
factor (Z’): Z’ =1 –3*(sp+sn)/|mp-mn|,
where s is the standard deviation and m
is the mean for positive (p) and negative
(n) controls.
27
The potency of inhibition by a given
chemical was measured by the percentage
of the inhibition of Atg4 cleavage activity,
which was calculated using the formula
modified from the one used for calculating
the percentage of cleavage (see above):
percentage of inhibition (%) = (RFUX -
RFUmin)/(RFUmax – RFUmin)*100%, in
which RFUX is the RFU ratio of 527 nm/
477 nm in the presence of a given
concentration of the chemical, RFUmin is
the ratio in the absence of chemicals, and
RFUmax is the ratio in the presence of a
maximal inhibitory concentration of the
chemical. IC50 was determined by plotting
the percentage of inhibition against the
concentration of the chemical, which was
fitted with a nonlinear 4-parameter fitting
method using SigmaPlot 10.0.
Statistical analysis. All experiments
have been performed at least three times.
Data shown are the mean ± SD from three
experiments and were subjected to t-test or
one-way ANOVA followed by Holm-
Sidak’s post-hoc analysis as indicated in
the figure legends. A level of p , 0.001
was considered significant.
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